Polaryx Therapeutics (PLYX) Research & Development (2025 - 2026)
Polaryx Therapeutics' (PLYX) quarterly Research & Development came in at $719000.0 in Q2 2026, up 51.05% year-over-year from $476000.0 in Q2 2025, and up 5.89% quarter-over-quarter from $679000.0 in Q1 2026.
Powered by 
Analysis
Polaryx Therapeutics (PLYX) Research & Development (2025 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Research & Development for 2 consecutive years, with $719000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Research & Development rose 51.05% year-over-year to $719000.0 in Q2 2026; TTM through Jun 2026 was $6.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.3 million, up 122.91% from the prior year.
- Research & Development was $719000.0 for Q2 2026 at Polaryx Therapeutics, up from $679000.0 in the prior quarter.
- Over five years, Research & Development peaked at $4.7 million in Q1 2025 and troughed at $476000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | 1.87 Bn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | 1.76 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 993.80 Mn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | 1.63 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | -486.00 Mn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | 651.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 529.60 Mn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | 202.02 Mn |
| 10 | Polaryx Therapeutics | 97.52 Mn | 85.98 Mn | - | 719,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 719,000.00 |
| Mar 31, 2026 | 679,000.00 |
| Jun 30, 2025 | 476,000.00 |
| Mar 31, 2025 | 4.72 Mn |